Trial ID # | NCT03601897 |
Phase | Ib/II |
Drug Class | Angiogenesis Inhibitors: Multi-targeted RTK |
Drug Name | Rebastinib |
Alternate Drug Names | multitargeted tyrosine kinase inhibitor DCC-2036 |
Drugs in Trial | Paclitaxel, Rebastinib |
Eligible Participant | Platinum resistant or refractory ovarian cancer |
Patients Enrolled | 38, median 4 prior therapies (2-7); 21% BRCA MUT, 87% w/ prior bevacizumab, 68% w/ prior PARP inhibitor |
Therapy Setting | Recurrence |
Study Design | Open-Label, Non-randomized |
Endpoints | ORR, DCR, DoR, PFS, evaluated per RECIST |
Efficacy | ORR: 38% (1CR, 12PR, n=34) |
Clinically Significant Adverse Events | Serious AE: reversible muscular weakness (n=1), urinary tract infection (n=1) |
Conclusion | Rebastinib+paclitaxel is well tolerated and shows encouraging anti-tumor activity in heavily pretreated patients with ovarian cancer |
Reference | Janku F et al. Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: Preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or metastatic solid tumors. AACR-NCI-EORTC (2019) abstr B055 Hamilton EP et al. A phase Ib/II study of rebastinib and paclitaxel in advanced/metastatic platinum-resistant ovarian cancer. Annals of Oncology (2021) 32 (suppl_5): abstract 728P Hamilton EP et al. Poster |